Table 4.
Summary of multivariate analyses of prognostic factors in the 576 NPC patients.
| Endpoint | Factor | HR | 95% CI | P |
|---|---|---|---|---|
| LRRFS | Age: <60 years vs. ≥60 years | 0.975 | 0.408–2.386 | 0.954 |
| Sex: male vs. female | 1.872 | 0.799–4.386 | 0.149 | |
| Clinical stage: III vs. IVA-B | 0.757 | 0.364–1.573 | 0.455 | |
| Regimen: NAC + IMRT vs. NAC + CCRT | 0.613 | 0.293–1.284 | 0.195 | |
| AC: No vs. Yes | 1.114 | 0.504–2.461 | 0.790 | |
| NAC cycle: <2 vs. ≥2 | 1.013 | 0.455–2.254 | 0.975 | |
| DMFS | Age: <60 years vs. ≥60 years | 1.539 | 0.704–3.364 | 0.280 |
| Sex: male vs. female | 1.356 | 0.723–2.543 | 0.342 | |
| Clinical stage: III vs. IVA-B | 0.552 | 0.309–0.985 | 0.044 | |
| Regimen: NAC + IMRT vs. NAC + CCRT | 0.565 | 0.314–1.017 | 0.057 | |
| AC: No vs. Yes | 0.831 | 0.424–1.628 | 0.589 | |
| NAC cycle: <2 vs. ≥2 | 1.675 | 0.888–3.161 | 0.111 | |
| PFS | Age: <60 years vs. ≥60 years | 1.130 | 0.627–2.039 | 0.684 |
| Sex: male vs. female | 1.525 | 0.897–2.593 | 0.120 | |
| Clinical stage: III vs. IVA-B | 0.665 | 0.412–1.072 | 0.094 | |
| Regimen: NAC + IMRT vs. NAC + CCRT | 0.541 | 0.332–0.884 | 0.014 | |
| AC: No vs. Yes | 0.880 | 0.514–1.508 | 0.642 | |
| NAC cycle: <2 vs. ≥2 | 1.263 | 0.748–2.130 | 0.382 | |
| OS | Age: <60 years vs. ≥60 years | 0.685 | 0.362–1.295 | 0.244 |
| Sex: male vs. female | 1.068 | 0.585–1.954 | 0.828 | |
| Clinical stage: III vs. IVA-B | 0.461 | 0.258–0.824 | 0.009 | |
| Regimen: NAC + IMRT vs. NAC + CCRT | 0.764 | 0.431–1.354 | 0.357 | |
| AC: No vs. Yes | 0.755 | 0.396–1.440 | 0.396 | |
| NAC cycle: <2 vs. ≥2 | 1.218 | 0.658–2.254 | 0.394 |
Abbreviations: LRRFS locoregional relapse-free survival, DMFS distant metastasis-free survival, PFS progression-free survival, OS overall survival, NAC neoadjuvant chemotherapy, AC adjuvant chemotherapy, CCRT concurrent chemoradiotherapy, IMRT intensity-modulated radiotherapy.